Sheet 1 of 4

0

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION** 

Use several sheets if necessary)

ATTY. DOCKET NO. 4-30961B APPLICATION NO. 10/807,736 APPLICANT OKUNO ET AL. FILING DATE MARCH 24, 2004

**Group** 1614

MAY 1 2 2006

#### **U.S. PATENT DOCUMENTS**

EXAMINER (WITTAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<del>a</del>	AA	5,358,941*	10/25/94	Bechard et al.			
	AB	4,608,368*	8/26/86	Blum et al.			
	AC	5,866,556*	2/2/99	Heikkilae-Hoikka			
	AD	6,416,964*	7/9/02	Rezka et al.			
	AE	5,116,864*	5/26/92	March et al.			
	AF	6,426,367*	7/30/02	Das			
•	AG	6,416,737*	7/9/02	Manolagas et al.			
	AH	6,677,320*	1/13/04	Diederich et al.			
	Al	4,814,326	3/21/89	Rosini et al.			
	AJ	4,927,814	5/22/90	Gall et al.	· · ·		
T.	AK	4,067,971	1/10/78	Francis et al.			
7	AL						

#### FOREIGN PATENT DOCUMENTS

0		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
4	АМ	WO 99/38998*	8/5/99	wo				
	AN	EP 0 998 934*	5/10/00	EP				
	AO	WO 99/04773*	2/4/99	wo				
-	AP	WO 88/00829*	2/11/88	wo ·				
Va	AQ	WO 95/29679*	11/9/95	wo				

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.)

	AR	Shipman, "Antitumor Activity", Leuk. Lymphoma, Vol. 32, Nos. 1/2, pp. 129-138, (XP000980146), (1998)*
	AS	Martodam, "The Effects of Dichloroethylene", Calcif. Tissue Int., Vol. 35, Nos. 4-5, pp. 512-519, (XP000980229), (1983)"
4	AT	Steiner et al., "Angiostatic activity of pamidronate (APD) and clodronate (Cl <sub>2</sub> MDP) in the chicken-chorioallantoic membrane assaypreliminary report," in Osteoclast Inhibition in the Management of Malignancy-Related Bone Disorders, An International Symposium held during the 15 <sup>th</sup> International Cancer Congress, Hamburg, Germany, August 1990, O.L.M. Bijvoet and A. Lipton (ed.)
EXAMIN	ER	DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 2 of 4

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30961B
APPLICATION NO.
10/807,736
APPLICANT
OCUNO ET AL.
FILING DATE
MARCH 24, 2004

Group 1614

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILII	NG DATE
	ВА							
	ВВ							
	вс		_		_			
	BD							
	BE			·	·			
	BF					<del></del>		
	BG		•					
	вн							
	ВІ							
	BJ							
	вк		•					
	BL							
			FOREIG	N PATENT DOCUMENTS				<u> </u>
	T	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION '
							YES	
Q	ВМ	EP 0 252 504	1/13/88	EP (English equiv. is U 4,927,814)			U U	
8	BM BN	EP 0 252 504 GB 2312165	1/13/88	EP (English equiv. is U 4,927,814)  GB				
9	ļ							
4	BN	GB 2312165	10/22/97	GB				
0	BN BO	GB 2312165 WO 99/29345	10/22/97	GB WO				
0	BN BO BP	GB 2312165 WO 99/29345 WO 96/39150 WO 96/05862A	10/22/97 6/17/99 12/12/96 2/29/96	GB WO WO WO Including Author, Title, Date, Pertine				
0	BN BO BP	GB 2312165 WO 99/29345 WO 96/39150 WO 96/05862A OTHER DOC M. Wegener et al., "El	10/22/97 6/17/99 12/12/96 2/29/96 UMENTS ( ffektive Schr 57 (1995)	GB WO WO Including Author, Title, Date, Pertine	der Applik	ation," Krank		S Arzt,
0	BN BO BP BQ	GB 2312165 WO 99/29345 WO 96/39150 WO 96/05862A  OTHER DOC M. Wegener et al., "Et Vol. 68(10), pp. 453-4 Bonabello et al., "Attiv	10/22/97 6/17/99 12/12/96 2/29/96 UMENTS ( ffektive Schr 57 (1995)	GB WO WO WO Including Author, Title, Date, Pertine merzreduktion bei intermittieren ca del disodio clodronato," Riv.	der Applik	ation," Krank ed. 17, pp. 1-		s Arzt,
	BN BO BP BQ	GB 2312165 WO 99/29345 WO 96/39150 WO 96/05862A  OTHER DOC M. Wegener et al., "Et Vol. 68(10), pp. 453-4 Bonabello et al., "Attiv	10/22/97 6/17/99 12/12/96 2/29/96 UMENTS ( ffektive Schr 57 (1995)	GB WO WO Including Author, Title, Date, Pertine	der Applik	ation," Krank ed. 17, pp. 1-		s Arzt,

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 3 of 4

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-30961B APPLICATION NO. 10/807,736 APPLICANT OKUNO ET AL. FILING DATE MARCH 24, 2004

Group 1614

EXAMINER (NITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)							
		Monk et al., "Remission of Psoriasis with Etidronate Treatment of Underlying Paget's Disease of						
4	DA	Bone," Dermatologica, Vol. 174, pp. 128-131 (1987)						
	DB	Marshall et al., "The Effect of Pamidronate on Lumbar Spine Bone Density and Pain in Osteoporosis Secondary to Systemic Mastocytosis," British Journal of Rheumatology, Vol. 36, pp. 393-396 (1997)						
	DC	Steiner, "Bisphosphonates inhibit angiogenesis in the chick chorioallantoic membrane," Abstract #404, Proceedings of the American Association for Cancer Research, Vol. 37, pg. 58 (1996)						
	DD	Diener, Clinical Review"Bisphosphonates for controlling pain from metastatic bone disease," Am J Health-Syst Pharm., Vol. 53, pp. 1917-27 (1996)						
	DE	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," Nature Medicine, Vol. 1(1), pp. 27-31 (1995)						
	DF	Matsunaga et al.,. "Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease," Am J Physiol Heart Circ Physiol, Vol. 288, pp. H2042-H2046 (2005)						
	DG	Gowda et al., "Treatment of refractory angina pectoris," International Journal of Cardiology, Vol. 101, pp. 1-7 (2005)						
3	DH	Oura et al., "Relief of Severe Pain by Pamidronate in a Case of Terminal Lung Carcinoma," Japanese Journal of Lung Cancer, Vol. 36(4), pp. 449-453 (1996)						
	DI							
	DJ							
	DK							
EXAMINE	Ř _	BAL DATE CONSIDERED 10 -26-06						

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 4 of 4

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-30961B APPLICATION NO. 10/807,738 APPLICANT OKUNO ET AL. FILING DATE MARCH 24, 2004

Group 1614

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	ВА							
	вв		-					
	вс							
	BD						,	
	BE							
	BF							
	BG							
	вн	·						
	ВІ						<b>†</b>	
	ВЈ						1.	
	ВК							
	BL							
			FOREIC	ON PATENT DOCUMENTS		<del></del>	<del></del>	
$\overline{}$		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
[]	вм	WO 96/16027	5/30/96	wo.				
<b>A</b>	BN	WO 98/43987*	10/8/98	wo				
	во					•		
	ВР							
	BQ	·						
		OTHER DOC	UMENTS	(including Author, Title, Date, Pertine	nt pages, E	tc.) .		
	BR					• "	-	
	BS			·				
	вт							
EXAMIN		Bal		DATE CONSIDERED	2B-0	6_		
*EXAMINE conformant	R: ce and r	Initial of reference consider not considered. Include a cop	ed, whether or py of this form	not citation is in conformance with MPE with the next communication to applicar	P 609: Drav	w a line through	citation i	f not in